Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05373459
Other study ID # Third COVID-19 booster
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 16, 2022
Est. completion date December 31, 2022

Study information

Verified date February 2024
Source Hong Kong Sanatorium & Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals. HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.


Recruitment information / eligibility

Status Completed
Enrollment 3167
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All full time staff members of the private hospital Exclusion Criteria: - History of COVID-19 before 2022

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Third COVID-19 booster
Third COVID-19 booster

Locations

Country Name City State
Hong Kong Hong Kong Sanatorium & Hospital Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Hong Kong Sanatorium & Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary COVID-19 Infection Number of participants with COVID-19 infected During 1 February - 31 March 2022
Primary Number of days return to work after COVID-19 infection Number of days return to work after COVID-19 infection During 1 February - 31 March 2022
See also
  Status Clinical Trial Phase
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Recruiting NCT05185817 - Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients Phase 2
Not yet recruiting NCT04876885 - The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations N/A
Active, not recruiting NCT05571657 - COVID-19 Booster Dose Reminder/Recall for Adolescents N/A
Completed NCT04888793 - Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Completed NCT04881396 - Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Recruiting NCT04871165 - Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Active, not recruiting NCT05293665 - Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine Phase 3
Active, not recruiting NCT05405283 - Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Phase 3
Recruiting NCT05508477 - UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) Phase 3
Recruiting NCT05471635 - Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Recruiting NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old Phase 3
Completed NCT05406908 - Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases Phase 4
Recruiting NCT04895007 - Comparative Evaluation of Covid-19 Vaccines Response
Recruiting NCT05831826 - Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
Recruiting NCT05096260 - Getting to Yes, Michigan! (G2YMI) N/A
Completed NCT04962906 - Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes Phase 2
Active, not recruiting NCT05027672 - Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. Phase 2